Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Simple blood test could spot Alzheimer's early

NCT ID NCT07294586

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is working on a blood test to help diagnose Alzheimer's disease. Researchers are measuring two specific markers in the blood of 200 people—some with Alzheimer's and some healthy—to see if these markers can reliably tell the difference. The goal is to create a simple, non-invasive diagnostic tool that could lead to earlier detection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to help diagnose Alzheimer's disease earlier and more accurately.
What could go wrong
This is an early exploratory study, so the biomarkers may not prove reliable enough for a diagnostic test. The results need validation in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Oct 2019

Finished

Jun 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of 200 individuals aged 50 to 85 years, divided into two cohorts: Healthy Volunteers (HV): 100 cognitively healthy individuals with no history of neurodegenerative disease. These participants will serve as controls for biomarker comparison. Alzheimer's Disease Patients (AD): 100 individuals clinically diagnosed with probable Alzheimer's disease based on neuropsychological testing, clinical evaluation, and imaging. These participants represent the target population for biomarker validation. Participants will be stratified by age and sex to ensure balanced representation across both groups. All subjects must be able to provide informed consent and comply with study procedures, including fasting sample collection and clinical assessments.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For All Participants (HV and AD groups): * Age between 50 and 85 years * Ability to understand and sign informed consent * Availability for the full duration of the study (24 months) * Fasting capability for morning sample collection (between 8:30-12:00) * Willingness to provide blood and urine samples for biomarker analysis and biobank storage Additional Criteria for Healthy Volunteers (HV): * No history or current diagnosis of neurodegenerative disease * Normal cognitive function confirmed by neuropsychological testing (e.g., MMSE score within normal range) * No significant abnormalities on brain imaging (CT or MRI if performed) * No use of medications affecting cognitive function Additional Criteria for Alzheimer's Disease Patients (AD): * Clinical diagnosis of probable Alzheimer's disease based on standardized criteria * Cognitive impairment confirmed by neuropsychological testing (e.g., MMSE score below threshold) * Supporting evidence from brain imaging (CT or MRI) and/or cerebrospinal fluid biomarkers (if available) * Stable medical condition allowing participation in study procedures Exclusion Criteria: For All Participants: * History of major psychiatric disorders (e.g., schizophrenia, bipolar disorder) * Significant neurological conditions other than Alzheimer's disease (e.g., Parkinson's disease, stroke) * Active malignancy or history of cancer within the past 5 years (except localized skin cancer) * Severe renal, hepatic, or cardiovascular disease * Current participation in another interventional clinical trial * Known blood disorders or conditions affecting red blood cell morphology or function * Recent blood transfusion (within 3 months) * Substance abuse or alcohol dependence * Inability to comply with study procedures Additional Exclusion for Healthy Volunteers: * Any cognitive complaints or subjective memory loss * First-degree family history of Alzheimer's disease (optional, depending on stratification strategy) * Use of psychoactive medications Additional Exclusion for Alzheimer's Disease Patients: * Diagnosis of mixed or atypical dementia * Rapidly progressive cognitive decline suggestive of other pathology * Contraindications to lumbar puncture (if CSF sampling is planned)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpitaux Civils de Colmar

    Colmar, Alsace, 68024, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.